{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:34:54Z","timestamp":1790537694531,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,4]],"date-time":"2020-12-04T00:00:00Z","timestamp":1607040000000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.nmd.2020.10.008","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T12:05:48Z","timestamp":1604577948000},"page":"959-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial"],"prefix":"10.1016","volume":"30","author":[{"given":"Francesco","family":"Muntoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Bertini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Comi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janbernd","family":"Kirschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lusakowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenio","family":"Mercuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariacristina","family":"Scoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Vuillerot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Burdeska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"El-Khairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo","family":"Fontoura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ives","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Gorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Fuerst-Recktenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2020.10.008_bib0001","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","article-title":"The genetics of spinal muscular atrophy: progress and challenges","volume":"12","author":"Farrar","year":"2015","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.nmd.2020.10.008_bib0002","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","article-title":"Childhood spinal muscular atrophy: controversies and challenges","volume":"11","author":"Mercuri","year":"2012","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.nmd.2020.10.008_bib0003","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1177\/0883073807305673","article-title":"Spinal muscular atrophy: clinical classification and disease heterogeneity","volume":"22","author":"Russman","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0004","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","article-title":"Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications","volume":"52","author":"Zerres","year":"1995","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0005","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal muscular atrophy: a timely review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0006","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and characterization of a spinal muscular atrophy-determining gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.nmd.2020.10.008_bib0007","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1073\/pnas.96.11.6307","article-title":"A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy","volume":"96","author":"Lorson","year":"1999","journal-title":"PNAS USA"},{"key":"10.1016\/j.nmd.2020.10.008_bib0008","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1086\/338627","article-title":"Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy","volume":"70","author":"Feldkotter","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.nmd.2020.10.008_bib0009","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00415-002-0811-4","article-title":"Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity","volume":"249","author":"Harada","year":"2002","journal-title":"J Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0010","doi-asserted-by":"crossref","first-page":"e33572","DOI":"10.1371\/journal.pone.0033572","article-title":"Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study","volume":"7","author":"Crawford","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2020.10.008_bib0011","unstructured":"Biogen Inc. SPINRAZA\u00ae (nusinersen) 2020 US prescribing information; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/209531lbl.pdf."},{"key":"10.1016\/j.nmd.2020.10.008_bib0012","unstructured":"Biogen Inc. SPINRAZA\u00ae (nusinersen) 2020 EMA prescribing information; Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/004312\/WC500229704.pdf."},{"key":"10.1016\/j.nmd.2020.10.008_bib0013","unstructured":"AveXis Inc. ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) 2020, US prescribing information; Available from: https:\/\/www.fda.gov\/media\/126109\/download."},{"key":"10.1016\/j.nmd.2020.10.008_bib0014","unstructured":"European Medicines Agency. Zolgensma. 2020 Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/zolgensma."},{"key":"10.1016\/j.nmd.2020.10.008_bib0015","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1212\/WNL.0000000000006502","article-title":"Evidence in focus: nusinersen use in spinal muscular atrophy: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology","volume":"91","author":"Michelson","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2020.10.008_bib0016","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1177\/0883073815627882","article-title":"Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience","volume":"31","author":"Hache","year":"2016","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0017","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/pan.13500","article-title":"A retrospective cohort study of children with spinal muscular atrophy type 2 receiving anesthesia for intrathecal administration of nusinersen","volume":"28","author":"Bielsky","year":"2018","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.nmd.2020.10.008_bib0018","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/pan.13160","volume":"27","author":"Hansen","year":"2017","journal-title":"Paediatr Anaesth"},{"key":"10.1016\/j.nmd.2020.10.008_bib0019","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1001\/jama.2015.1149","article-title":"Neurotoxicity of generic anesthesia agents in infants and children: an orphan research question in search of a sponsor","volume":"313","author":"Psaty","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2020.10.008_bib0020","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.nmd.2019.08.007","article-title":"Intrathecal administration of nusinersen in adult and adolescent patients with spinal muscular atrophy and scoliosis: transforaminal versus conventional approach","volume":"29","author":"Bortolani","year":"2019","journal-title":"Neuromusc Disord"},{"key":"10.1016\/j.nmd.2020.10.008_bib0021","unstructured":"Genentech. Evrysdi (risdiplam) US prescribing information 2020; Available from: https:\/\/www.gene.com\/download\/pdf\/evrysdi_prescribing.pdf."},{"key":"10.1016\/j.nmd.2020.10.008_bib0022","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1007\/s00018-018-2849-1","article-title":"The role of survival motor neuron protein (SMN) in protein homeostasis","volume":"75","author":"Chaytow","year":"2018","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.nmd.2020.10.008_bib0023","first-page":"597","article-title":"Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick? Nature reviews","volume":"10","author":"Burghes","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.nmd.2020.10.008_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bbagrm.2016.12.008","article-title":"Diverse role of survival motor neuron protein","volume":"1860","author":"Singh","year":"2017","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nmd.2020.10.008_bib0025","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1002\/jnr.22106","article-title":"Mitochondrial dysfunction in a neural cell model of spinal muscular atrophy","volume":"87","author":"Acsadi","year":"2009","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.nmd.2020.10.008_bib0026","doi-asserted-by":"crossref","first-page":"3395","DOI":"10.1093\/hmg\/ddw262","article-title":"Motor neuron mitochondrial dysfunction in spinal muscular atrophy","volume":"25","author":"Miller","year":"2016","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.nmd.2020.10.008_bib0027","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamaneurol.2015.0178","article-title":"Impaired muscle mitochondrial biogenesis and myogenesis in spinal muscular atrophy","volume":"72","author":"Ripolone","year":"2015","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.nmd.2020.10.008_bib0028","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/ph3020345","article-title":"Olesoxime (TRO19622): a novel mitochondrial-targeted neuroprotective compound","volume":"3","author":"Bordet","year":"2010","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.nmd.2020.10.008_bib0029","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1111\/bph.12094","article-title":"Olesoxime protects embryonic cortical neurons from camptothecin intoxication by a mechanism distinct from BDNF","volume":"168","author":"Gouarne","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bph.12939","article-title":"Protective role of olesoxime against wild-type alpha-synuclein-induced toxicity in human neuronally differentiated SHSY-5Y cells","volume":"172","author":"Gouarne","year":"2015","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0031","unstructured":"AG FH-LR. 2020 Clinical trial results: open-label phase Ib, dose-ranged, single and multiple dose study to assess safety and pharmacokinetics of TRO19622 in 6-25 year old spinal muscular atrophy (SMA) patients. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2006-006845-14\/results."},{"key":"10.1016\/j.nmd.2020.10.008_bib0032","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(17)30085-6","article-title":"Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"16","author":"Bertini","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0033","unstructured":"ClinicalTrials.gov. 2020 NCT01302600: safety and efficacy of Olesoxime (TRO19622) in 3-25 years SMA patients. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302600."},{"key":"10.1016\/j.nmd.2020.10.008_bib0034","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.rehab.2013.10.002","article-title":"Development and validation of a motor function classification in patients with neuromuscular disease: the NM-score","volume":"56","author":"Vuillerot","year":"2013","journal-title":"Ann Phys Rehabil Med"},{"key":"10.1016\/j.nmd.2020.10.008_bib0035","unstructured":"B\u00e9rard C, Girardot F, Payan C. User's manual: MFM-32 & MFM-20; Available from: https:\/\/mfm-nmd.org\/get-a-user-manual\/?lang=en."},{"key":"10.1016\/j.nmd.2020.10.008_bib0036","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.nmd.2004.04.004","article-title":"Concerns about the design of clinical trials for spinal muscular atrophy","volume":"14","author":"Crawford","year":"2004","journal-title":"Neuromusc Disord"},{"key":"10.1016\/j.nmd.2020.10.008_bib0037","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromusc Disord"},{"key":"10.1016\/j.nmd.2020.10.008_bib0038","unstructured":"ClinicalTrials.gov. 2020 NCT02628743: a study to evaluate long term safety, tolerability, and effectiveness of olesoxime in patients with spinal muscular atrophy; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02628743."},{"issue":"Suppl 16","key":"10.1016\/j.nmd.2020.10.008_bib0039","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","article-title":"Lung volumes and forced ventilatory flows","volume":"6","author":"Quanjer","year":"1993","journal-title":"Eur Respir J"},{"key":"10.1016\/j.nmd.2020.10.008_bib0040","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ppul.1950190209","article-title":"Spirometric reference values for white European children and adolescents: polgar revisited","volume":"19","author":"Quanjer","year":"1995","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0041","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1469-8749.2004.tb00508.x","article-title":"Height prediction from ulna length","volume":"46","author":"Gauld","year":"2004","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0042","author":"Elia","year":"2003"},{"key":"10.1016\/j.nmd.2020.10.008_bib0043","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1016\/j.apmr.2013.01.014","article-title":"Responsiveness of the motor function measure in patients with spinal muscular atrophy","volume":"94","author":"Vuillerot","year":"2013","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2020.10.008_bib0044","unstructured":"Clinicaltrials.gov. 2020 NCT02391831: prospective study of the natural history of patients with Type 2 and 3 spinal muscular atrophy (NatHis-SMA). Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT02391831?term=NCT02391831&draw=2&rank=1."},{"key":"10.1016\/j.nmd.2020.10.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201004","article-title":"Prospective and longitudinal natural history study of patients with type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study","volume":"13","author":"Chabanon","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2020.10.008_bib0046","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","article-title":"Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials","volume":"26","author":"Mercuri","year":"2016","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.1016\/j.nmd.2020.10.008_bib0047","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1177\/088307389400900321","article-title":"Pulmonary function in spinal muscular atrophy","volume":"9","author":"Samaha","year":"1994","journal-title":"J Child Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0048","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13023-020-01367-y","article-title":"Natural history of lung function in spinal muscular atrophy","volume":"15","author":"Wijngaarde","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"25","key":"10.1016\/j.nmd.2020.10.008_bib0049","first-page":"1","article-title":"Current treatment options in neurology-SMA therapeutics","volume":"21","author":"Waldrop","year":"2019","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2020.10.008_bib0050","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12883-019-1244-3","article-title":"Assessment of fatigability in patients with spinal muscular atrophy: development and content validity of a set of endurance tests","volume":"19","author":"Bartels","year":"2019","journal-title":"BMC Neurol"},{"key":"10.1016\/j.nmd.2020.10.008_bib0051","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13023-018-0904-5","article-title":"A continuous repetitive task to detect fatigability in spinal muscular atrophy","volume":"13","author":"Stam","year":"2018","journal-title":"Orphanet J Rare Dis"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960896620306453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:09:43Z","timestamp":1760774983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960896620306453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0960896620306453"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2020.10.008","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2020.10.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}